2. Eli Lilly and Company (NYSE:LLY)
Eli Lilly and Company (NYSE: LLY) takes the No. 2 position as perhaps the most recognizable pure growth story among the healthcare stocks in this ranking.
A decade ago, very few mainstream investors would have expected an established pharmaceutical company to become one of Wall Street’s hottest growth stocks. The rise of GLP-1 medicines changed that equation dramatically.
Eli Lilly and Company (NYSE: LLY) develops treatments across diabetes, cancer, neurological disorders and other major medical categories, but Mounjaro and the broader obesity and metabolic medicine opportunity have fundamentally transformed investor expectations surrounding the company.
Mounjaro has emerged as one of the leading medications associated with the GLP-1 revolution, while the company’s existing pharmaceutical portfolio includes important products such as oncology treatment Verzenio and diabetes medicine Trulicity.
The scale of the obesity opportunity is difficult to overstate.
Obesity affects hundreds of millions of people globally and is associated with increased risk of numerous chronic diseases. A successful pharmaceutical treatment therefore does not address a narrow niche market. It potentially reaches one of the largest patient populations in medicine.
CFRA analyst Sel Hardy believes Eli Lilly and Company (NYSE: LLY) is particularly well positioned to benefit from both the aging U.S. population and continued expansion of GLP-1 demand.
One of the most intriguing catalysts identified by Hardy is Foundayo, the newly launched oral GLP-1 weight-loss medicine referenced in the supplied analysis. An oral treatment could potentially expand accessibility and convenience compared with injectable medications, making the product’s commercial development particularly important to watch.
Convenience should not be underestimated in pharmaceutical competition.
When multiple drugs produce strong clinical results, ease of use can become an important differentiator. A treatment patients can take more conveniently could improve adoption and expand the overall market.
Eli Lilly and Company (NYSE: LLY) is also strengthening its pipeline through acquisitions. The recent acquisition of Kelonia is expected to add additional value and broaden the company’s longer-term development opportunities.
CFRA has a “buy” rating and a $1,355 price target for Eli Lilly and Company (NYSE: LLY), compared with a July 30 closing price of $1,154.97. Based on those figures, the analyst target represents approximately 17% potential upside.
That is notable because Eli Lilly and Company (NYSE: LLY) is already valued as one of the world’s premier healthcare companies.
Investors looking at Eli Lilly and Company (NYSE: LLY) therefore face a different question than they might with a traditional value stock. The issue is not whether the company has growth. Few investors seriously dispute that. The bigger issue is how much of that growth is already reflected in the valuation.
Still, the underlying fundamental story remains difficult to ignore.
Eli Lilly and Company (NYSE: LLY) has exposure to diabetes, obesity, cancer and neurological disease, several of the largest healthcare markets in the world. It has established commercial products, an expanding pipeline and tremendous momentum in the GLP-1 market.
For investors searching for the best healthcare stocks to buy in 2026, GLP-1 stocks, pharmaceutical growth stocks and companies benefiting from rising obesity-treatment demand, Eli Lilly and Company (NYSE: LLY) remains one of the industry’s defining names.
